

Together we soar.


JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and persistence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients.

We continue to build upon our **49-year legacy** in Japan while expanding our global footprint with trials in the US, Asia, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies.



Development Pipeline

Programs in Clinical Development or Entering Clinical Trials within the Next Years



Programs in Earlier Stages of Development




* Development of a manufacturing process to generate material for clinical application.
 ** Approved in Japan March 2021 and launched in May 2021.



J-Brain Cargo® Technology

Our proprietary technology, **J-Brain Cargo®**, enables us to develop enzyme therapies that penetrate the central nervous system (CNS), and thereby address the disease symptoms in the CNS in addition to treating the disease in the rest of the body.

Mechanism of Action of J-Brain Cargo® Technology to Bring Biotherapeutics Across the Blood-Brain Barrier



Office Locations

JCR USA:

12544 High Bluff Drive, Suite 340,
San Diego, CA 92130, U.S.A.

JCR DO BRASIL:

Avenida das Nações Unidas, 14261 – Torre B,
27º Andar, Sala 122, Vila Gertrudes,
So Paulo, Brazil

JCR Europe B.V.:

Bargelaan 200, 2333 CW Leiden,
The Netherlands

Headquarters:

3-19 Kasuga-cho, Ashiya, Hyogo,
659-0021 Japan

Research Institute:

2-2-9 Murotani, Nishi-ku, Kobe, Hyogo,
651-2241 Japan

Bioresearch Center:

1-5-4 Murotani, Nishi-ku, Kobe, Hyogo,
651-2241 Japan

Kobe Science Park Center:

7-3-15 Ibukidai Higashimachi, Nishi-ku, Kobe, Hyogo,
651-2242 Japan

Public: Tokyo SE 4552 | Employees: ~930

Recent Milestones

JR-141, under development for Mucopolysaccharidosis (MPS) Type II or Hunter syndrome

February 2022: Dosed first patient in global phase 3 clinical trial of JR-141

January 2023: Granted Rare Pediatric Disease Designation for JR-141 for the treatment of MPS II by US FDA

JR-171, under development for MPS Type I or Hurler syndrome

2020: First patient dosed in global phase 1/2 clinical trial of JR-171

2021: Received Orphan Drug Designation for JR-171 from both FDA and European Commission and Fast Track Designation from FDA

JR-441, under development for MPS Type IIIA or Sanfilippo syndrome Type A

January 2022: Received Orphan Drug Designation for JR-441 from European Commission

October 2023: Dosed first patient in global phase 1/2 clinical trial of JR-441

December 2023: Received Orphan Drug Designation for JR-441 from US FDA

JR-471, under development for Fucosidosis

October 2022:

- Entered development phase of JR-471
- Concluded a licensing contract for commercialization of a Fucosidosis therapeutic with MEDIPAL HOLDINGS

JR-479, under development for GM2 Gangliosidosis

March 2022: Entered development phase of JR-479

Corporate

February 2022: IZCARGO® received the 2022 *WORLD Symposium™* New Treatment Award

October 2022: MEDIPAL HOLDINGS and JCR Pharmaceuticals agree on the granting of exclusive negotiation rights for global Commercialization targeting four ultra-rare diseases and conclude a licensing contract for the commercialization of a fucosidosis therapeutic

March 2023: JCR Pharmaceuticals announces research collaboration, option and license agreement with Alexion to develop a therapy using J-Brain Cargo® for neurodegenerative disease

May 2023: Angelini Pharma and JCR Pharmaceuticals announce global collaboration for the development and commercialization of novel biologic therapies in epilepsy

June 2023: Received the 48th Inoue Harushige Prize for Therapeutics for Lysosomal Storage Disorders with an Original BBB Penetrating Technology together with William M. Pardridge, M.D., Distinguished Professor Emeritus at UCLA

For more information:

→ jcrpharm.co.jp ✉ ir-info@jp.jcrpharm.com

Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

